Press release
STADA expands Consumer Healthcare in Asia-Pacific and acquires rights to Nizoral Cream™ in certain markets, including Thailand
- STADA acquires rights to Nizoral Cream in Thailand, Vietnam, and the Philippines as well as the trademark rights (TM) in Hong Kong, Australia, Indonesia, Malaysia, New Zealand and Singapore
- This transaction continues the successful acquisition of STADA’s Nizoral Brands in several EMEA markets
- STADA EVP Emerging Markets Stephane Jacqmin: “We are very pleased about this important expansion step in the Asia-Pacific region. This asset acquisition further strengthens STADA’s role as a partner of choice in consumer healthcare”
Bangkok, Thailand 19 August 2024 – The pharmaceutical company STADA is expanding its Consumer Healthcare business in the Asia-Pacific region with the acquisition of Nizoral Cream from Janssen Pharmaceutica NV, a Johnson & Johnson company.
Under the terms of the agreement, STADA acquires the existing distribution and Nizoral Cream business in the markets Thailand, Vietnam, and the Philippines as well as the trademark rights (TM) in Hong Kong, Australia, Indonesia, Malaysia, New Zealand and Singapore.
This transaction is an extension of a previous asset deal to the APAC region. In 2018, STADA successfully acquired the Nizoral brand in key EMEA markets.
STADA EVP Stephane Jacqmin Emerging Markets: “We are delighted to take this important step of expansion in the Asia-Pacific region. This partnership further strengthens STADA´s role as a partner of choice in consumer healthcare”.
About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in approximately 115 countries. In financial year 2023, STADA achieved group sales of EUR 3,734.8 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 802.1 million. As of 31 December 2023, STADA employed 11,667 people worldwide.
STADA information for journalists:
STADA Arzneimittel AG – Media Relations TQPR Thailand
Stadastrasse 2-18 Phone: 02 260 5820
61118 Bad Vilbel – Germany E-Mail: mae@tqpr.com
Phone: +49 (0) 6101 603-165
Fax: +49 (0) 6101 603-215
E-Mail: press@stada.de
Or visit us on the Internet at www.stada.com/press
STADA information for capital market participants:
STADA Arzneimittel AG – Investor & Creditor Relations
Stadastrasse 2-18
61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-4689
Fax: +49 (0) 6101 603-215
E-mail: ir@stada.de
Or visit us on the Internet at www.stada.com/investor-relations